Tamarac Seniors Diagnosed with Atrial Fibrillation Join Innovative Research Study

New potential treatment option may provide an alternative for those not suitable for current anticoagulant treatments.

BOSTON--(BUSINESS WIRE)--A global research study is now available in Tamarac, Fla., for an investigational treatment to help patients with a history of atrial fibrillation (AFib) decrease their risk of stroke. Patients with AFib are known to have a four to five times higher risk of stroke than the general population. Anticoagulant treatments are regularly prescribed by physicians and proven to effectively reduce the incidence of strokes. However, data from multiple registries and claims-based data analyses have shown that anywhere from 40% to 60% of AFib patients are not being optimally treated today. This is especially true in older adults, those with kidney or liver disease, those needing concomitant antiplatelet therapy, and patients with other factors associated with an increased risk of bleeding.

The LILAC-TIMI 76 phase 3 study is currently enrolling for patients to evaluate the efficacy and safety of abelacimab in high-risk patients with AFib deemed unsuitable for current anticoagulants by their physicians. Abelacimab is a dual-acting Factor XI inhibitor that may offer a safer treatment option. By doing so, the hope is that the current treatment gap is closed so that more eligible patients can get the treatment they deserve.

“This study is particularly important for our community because the prevalence of AFib in South Florida is higher than the national average,” said Dr. Brad Lipson, Principal Investigator for Care Access - Tamarac. “It will provide valuable data that can be used to improve the prevention, diagnosis, and management of AFib. I encourage all eligible residents of Miami-Dade, Broward, and Palm Beach counties to participate in this important research.”

This research study is currently enrolling for adults ages 65+ with AFib, at high risk of stroke, and currently not taking certain oral anticoagulants or having stopped taking them within the last three months. To learn more, visit careaccess.com/studies or contact Care Access at [phone].

Care Access opened its Tamarac location in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible to South Florida residents.

About Care Access
Care Access is a global research company helping to accelerate the arrival of new medicines. With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 20 biopharmaceutical companies. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation. For research sponsors, Care Access offers three core services: (1) global network of research sites, (2) community screenings to expand a study’s reach, and (3) staffing, on-demand physical space expansion, and training services to support all research sites on a study.

To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com.